Skip to main content

Adicet Bio Value Stock - Dividend - Research Selection

Adicet Bio Inc

ISIN: US0070021086, WKN: A2QESQ

Market price date: 16.05.2022
Market price: 12,90 USD

Adicet Bio Inc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 06-02-2022
Cash flow
Net operating cash flow -41.552.000
Capital Expenditures -990.000
Free cash flow -42.542.000
Balance sheet
Total Equity 109.827.000
Liabilities & Shareholders equity 153.835.000
Income statement
Net income -36.678.000
Eps (diluted) -7,041
Diluted shares outstanding 5.208.890
Net sales/revenue 17.903.000

Fundamental ratios calculated on: 16-05-2022

Key figures 16-05-2022
Cash flow
P/C -1,62
P/FC -1,58
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization67.194.680,00 USD
CountryUnited States
IndicesNASDAQ Comp.,Russell 3000
SectorsHealth Care Distributors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2020-09-16,1.000000/7.000000; 2005-01-12,3.0000/2.0000; 2005-01-11,3.0000/2.0000; 2004-01-06,3.0000/2.0000; 2004-01-05,3.0000/2.0000; 2003-01-04,3.0000/2.0000; 2003-01-03,3.0000/2.0000; 1998-04-15,3.0000/2.0000; 1998-04-14,3.0000/2.0000; 1995-12-14,11.0000/10.0000; 1992-12-15,6.0000/5.0000; 1992-12-14,6.0000/5.0000; 1991-12-10,11.0000/10.0000; 1991-12-09,11.0000/10.0000; 1990-06-06,104.0000/100.0000; 1990-06-05,104.0000/100.0000; 1989-12-11,100.0000/104.0000; 1989-06-06,104.0000/100.0000; 1988-12-12,100.0000/104.0000; 1988-06-07,100.0000/104.0000; 1987-12-15,100.0000/104.0000; 1987-06-08,104.0000/100.0000; 1986-10-07,100.0000/104.0000; 1986-03-24,100.0000/104.0000; 1985-11-26,100.0000/104.0000; 1985-10-22,100.0000/104.0000; 1985-03-25,100.0000/104.0000; 1985-02-11,3.0000/2.0000; 1984-10-02,100.0000/104.0000; 1984-03-26,100.0000/104.0000; 1982-12-31,4.0000/3.0000

Description of the company

Aceto Corporation (Aceto) is primarily engaged in the sourcing, regulatory support, quality assurance, marketing, sales and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries. The Company operates in three segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals. The Company has operations in nine countries; it distributes more than 1,100 chemical compounds used principally as finished products or raw materials. The Company has presence in China, Germany, France, the Netherlands, Singapore, India, Hong Kong, the United Kingdom and the United States, along with warehouses worldwide.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


SEC filings reveal massive selling in media names, including Disney and Comcast

Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

Shareholders in Adicet Bio, Inc. ( NASDAQ:ACET ) had a terrible week, as shares crashed 21% to US$11.83 in the week...

Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates

MENLO PARK, Calif. & BOSTON, May 12, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2022.

ADICET BIO, INC. Management's Discussion and Analysis of Financial Condition and Resultsof Operations. (form 10-Q)

You should read the following discussion and analysis of our financial conditionand results of operations together with our consolidated financial statementsand related notes included elsewhere in... | May 12, 2022

Further weakness as Adicet Bio (NASDAQ:ACET) drops 31% this week, taking one-year losses to 17%

It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...

Adicet Bio reports Q1 EPS (12c), consensus (18c)

"We made steady prog... ACET

Notable Two Hundred Day Moving Average Cross - ACET

In trading on Wednesday, shares of Adicet Bio Inc (ACET) crossed below their 200 day moving average of $11.81, changing hands as low as $11.29 per share - Adicet Bio Inc shares are currently trading down about 6.3% on the day. - ACET.

Cable companies to offer effectively free internet to low-income homes

The news means that tens of millions of households could receive high-speed internet at no cost, according to the White House.

Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies

MENLO PARK, Calif. & BOSTON, May 05, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced data from a preclinical evaluation of ADI-001 at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting taking place in San Francisco, May 4-7, 2022. ADI-001 is currently being evaluated in an ongoing dose escalation Phase 1

ADICET BIO, INC. : Regulation FD Disclosure (form 8-K)

Item 7.01 Regulation FD Disclosure.On May 5, 2022, Adicet Bio, Inc. issued a press release titledAdicet Presents Preclinical Data at the ISCT Annual Meeting HighlightingPotential Advantages of... | May 5, 2022